Dr. Devalingam Mahalingam is a faculty member in the division of hematology/oncology. He completed his internal medicine training and medical oncology fellowship in Ireland, during which time he also concurrently received his doctorate research in 2008 with a focus on drug development. He then completed the advanced fellowship program at the Institute for Drug Development at the Cancer Therapy & Research Center, before his appointment as assistant professor of medicine at the CTRC. His career is dedicated to clinical and laboratory research in gastrointestinal and genitourinary cancers. Among his clinical research interests is a focus on hepatocellular cancer in the gastrointestinal clinic. His groundbreaking research has been presented in many scientific seminars and large international meetings.
Al-Rajabi, R., Patel, S., Ketchum, N. S., Jaime, N. A., Lu, T. W., Pollock, B. H. & Mahalingam, D. Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction. J. Gastrointest. Oncol. 6, 259-267 (2015). PMID: 26029452; PMCID: PMC4397242
Birzele, F., Voss, E., Nopora, A., Honold, K., Heil, F., Lohmann, S., Verheul, H. M., Le Tourneau, C., Delord, J. P., van Herpen, C. M., Mahalingam, D., Coveler, A. L., Meresse Naegelen, V., Weigand, S., Runza, V. & Cannarile, M. CD44 isoform status predicts response to treatment with anti-CD44 antibody in cancer patients. Clin. Cancer Res. 5;21(12):2753-62 (2015). PMID: 25762343
Mahalingam, D., Patel, S., Nuovo, G., Gill, G., Selvaggi, G., Coffey, M. & Nawrocki, S. T. The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer. BMC Cancer 15, 513-015-1518-0 (2015). PMID: 26156229; PMCID: PMC4496814